Surface Starts Phase 1/2 Study of Antibody, in Advanced Solid Tumors

 SRF114 is designed to preferentially deplete CCR8⁺ Treg cells within the tumor microenvironment and has demonstrated highly specific CCR8-exclusive binding and reduced tumor growth in pre-clinical studies

Initial clinical data anticipated in 2024

https://www.biospace.com/article/releases/surface-oncology-announces-first-patient-dosed-in-a-phase-1-2-study-evaluating-srf114-a-potential-best-in-class-anti-ccr8-antibody-in-patients-with-advanced-solid-tumors/